Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA.

J Bone Miner Res. 2012 Jul;27(7):1480-6. doi: 10.1002/jbmr.1606.

2.

Interpretation and use of FRAX in clinical practice.

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV; Task Force of the FRAX Initiative.

Osteoporos Int. 2011 Sep;22(9):2395-411. doi: 10.1007/s00198-011-1713-z. Epub 2011 Jul 21. Review.

PMID:
21779818
3.

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Kanis JA, Johansson H, Oden A, McCloskey EV.

Osteoporos Int. 2011 Aug;22(8):2347-55. doi: 10.1007/s00198-010-1474-0. Epub 2011 Feb 2. Erratum in: Osteoporos Int. 2011 Aug;22(8):2357-8.

PMID:
21287148
4.

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2010 Oct;47(4):729-35. doi: 10.1016/j.bone.2010.06.009. Epub 2010 Jun 18.

PMID:
20601292
5.

From relative risk to absolute fracture risk calculation: the FRAX algorithm.

McCloskey EV, Johansson H, Oden A, Kanis JA.

Curr Osteoporos Rep. 2009 Sep;7(3):77-83.

PMID:
19723465
6.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.

7.

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2009 Jun;44(6):1049-54. doi: 10.1016/j.bone.2009.02.014. Epub 2009 Feb 28.

PMID:
19254788
8.

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.

McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA.

Osteoporos Int. 2009 May;20(5):811-7. doi: 10.1007/s00198-008-0786-9. Epub 2008 Nov 11.

PMID:
19002369
9.

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.

J Bone Miner Res. 2008 Dec;23(12):1923-34. doi: 10.1359/jbmr.080710.

10.

The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.

Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM.

Biochem Pharmacol. 2007 Aug 1;74(3):438-47. Epub 2007 Apr 27.

PMID:
17531955
11.

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ.

J Clin Endocrinol Metab. 2005 May;90(5):2816-22. Epub 2005 Feb 22.

12.

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.

N Engl J Med. 2004 Jan 29;350(5):459-68.

13.

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.

Bone. 2003 Oct;33(4):522-32.

PMID:
14555255
14.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10517716
15.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

[No authors listed]

World Health Organ Tech Rep Ser. 1994;843:1-129. Review. No abstract available.

PMID:
7941614

Supplemental Content

Support Center